Investment in the biotech sector has had a part to play in the increasing number of biological and biosimilar makers in South Korea, with increased state-led support and private sector pledges.

In April 2019, South Korea’s government announced that it would be investing nearly three trillion Won (US$2.6 billion) in 2019 into biotech-related research and development, and commercialization, in an effort to promote innovative growth. But it is not just increased government spending, pharmaceutical companies are also increasing investment in biologicals, with Celltrion and Samsung both pledging billions of dollars in a bid to expand their presence in the biosimilar field [1].

Domestic development of biosimilars is being carried out in South Korea by firms including Celltrion, Samsung Bioepis, LG Chem, GC Green Cross, Chong Kun Dang, CJ Healthcare and Dong-A ST.

Given the local support and the lucrative nature of the biosimilars market, it is therefore perhaps not surprising that the pipelines of these seven Korean firms is looking particularly healthy when it comes to biosimilars.

The following series of articles discuss in more details the biosimilar pipelines for South Korean companies developing biosimilars.

Reference
1. GaBI Online - Generics and Biosimilars Initiative. South Korea increases investment in biologicals [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Jul 24]. Available from: www.gabionline.net/Biosimilars/General/South-Korea-increases-investment-in-biologicals

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing. 

Copyright – Unless otherwise stated all contents of this website are © 2020 Pro Pharma Communications International. All Rights Reserved.